GlaxoSmithKline: Making an impact on emerging markets

Authored by Abbas Hussain, Senior Partner, C-Bridge Capital

Criticaleye recently caught up with Abbas Hussain, President, Emerging Markets at GlaxoSmithKline, to discuss the state of  emerging markets and the initial stages of GSK’s low-cost drug plan, a revolutionary scheme set to change the face of the pharmaceutical industry.

Share this with your Community





Click here to download this insight

DOWNLOAD INSIGHT



Related Insights

Read, watch & listen to some of the latest thought leadership from our Community.


Click here to download this insight

Where M&A Value is Won or Lost

M&A can create significant opportunities for growth, but realising the expected value often depends on how effectively organisations manage the people side of a transaction. This report by LACE Partners explores how...


Jane Pateman, NED at Knights plc: What Changes from CPO to NED?

Moving from CPO to NED means shifting from execution to influence, challenge and oversight. In this episode, Bridgette Hall, Senior Editor at Criticaleye, speaks with Jane Pateman, NED at Knights plc and Critical...


Christina Chan, CFO, Asia Pacific at Marriott International on Leading as a Regional CFO

Christina Chan, CFO, Asia Pacific excluding China for Marriott International spoke to us about her career journey, leading as a regional CFO and finance as a driver for growth. Discussion points include: ...


1 2 3 4 5 6 7 8 9 10
Displaying 1 to 3 of 215




NatWest Group Stream British Land AlixPartners Lightsource bp Rolls-Royce NATS Legal & General Global Payments LACE Partners Drax Group plc E.ON UK Mayborn Group GlaxoSmithKline plc London Stock Exchange Group Hitachi Solutions